CK and Aldolase Are NOT Always Elevated in PM-Scl-75 Associated Scleromyositis
No, creatine kinase (CK) and aldolase are not always elevated in PM-Scl-75 associated scleromyositis, and this is a critical diagnostic pitfall that can lead to missed or delayed diagnosis. In fact, approximately 50% of systemic sclerosis-myopathy patients may have normal CK levels despite active muscle disease 1, 2.
Key Clinical Patterns of Muscle Enzyme Elevation
Variable CK Elevation in SSc-Myopathy
- Only 48.3% of SSc-myopathy patients demonstrate elevated CK levels, meaning more than half have normal CK despite clinically significant muscle involvement 3
- Anti-PM/Scl-100 antibodies specifically associate with CK elevation, while anti-PM/Scl-75 antibodies do not consistently correlate with elevated muscle enzymes 1
- Proximal weakness can occur with normal CK in 15% of SSc patients, representing a distinct clinical phenotype that still carries significant mortality risk 2
Aldolase as a More Sensitive Marker
- Aldolase may be elevated when CK remains normal in various myopathies, including dermatomyositis and overlap syndromes 4
- Aldolase >9 U/L predicts subsequent myopathy development in SSc patients with a hazard ratio of 10.3, even when CK is normal 5
- In dermatomyositis patients with selective aldolase elevation and normal CK, perimysial pathology is found in 50% of cases 4
Clinical Phenotypes Based on Enzyme Patterns
Concurrent Proximal Weakness and CK Elevation (4% of SSc patients)
- Represents severe, inflammatory SSc phenotype with diffuse cutaneous disease 2
- Associated with 3.6-fold increased mortality (95% CI 1.9-6.6) 2
- More frequent tendon friction rubs, synovitis, and digital ulceration 2
Proximal Weakness with Normal CK (15% of SSc patients)
- Still carries 2.1-fold increased mortality risk (95% CI 1.4-3.0) 2
- Associated with multimorbidity and cardiopulmonary disease including pulmonary arterial hypertension 2
- Demonstrates impaired physical function with reduced six-minute walk distance and higher HAQ-DI scores 2
CK Elevation Alone Without Weakness (24% of SSc patients)
- More common in men with anti-Scl-70 positivity 2
- Paradoxically associated with better survival (HR 0.7,95% CI 0.4-1.1) compared to those without muscle involvement 2
Diagnostic Workup Algorithm
Initial Laboratory Assessment
Blood testing should include CK, aldolase, AST, ALT, and LDH as all can be elevated in myositis, though patterns vary 6, 7. The most abnormal enzyme should be tracked for monitoring 8.
- Inflammatory markers (ESR and CRP) are typically elevated in SSc-myopathy 3
- Check autoantibody profile including anti-PM/Scl-75 and anti-PM/Scl-100 separately, as they define distinct clinical subsets 1
- Anti-PM/Scl-75 is more common in diffuse SSc (found in 10.4% of SSc patients) and associates with younger age, joint contractures, and more active disease 1
- Anti-PM/Scl-100 (found in 7.1% of SSc patients) specifically correlates with CK elevation but less frequent gastrointestinal involvement 1
When Muscle Enzymes Are Normal But Clinical Suspicion Remains High
- Proceed with MRI imaging of proximal muscles using T1-weighted, T2-weighted sequences with fat suppression and STIR 9
- Whole-body MRI may be more accurate than selected muscle groups in capturing disease extent in SSc-myopathy 3
- Consider EMG, though fibrillation potentials are less frequent (50%) in dermatomyositis patients with normal CK compared to those with elevated CK (90.5%) 4
- Muscle biopsy remains definitive when diagnosis is uncertain, particularly to identify perimysial pathology patterns 6
Cardiac Evaluation Is Mandatory
- Check troponin to evaluate myocardial involvement regardless of CK level 6, 7
- Obtain ECG and echocardiogram; consider cardiac MRI 6
- Myocardial involvement mandates permanent discontinuation of immune checkpoint inhibitors if present, though this applies to checkpoint inhibitor-induced myositis rather than SSc-myopathy 7
Critical Pitfalls to Avoid
Do Not Rely on CK Alone
The absence of CK elevation does not exclude clinically significant myopathy in SSc patients. This is particularly true for anti-PM/Scl-75 positive patients who may have severe muscle involvement with normal or minimally elevated CK 1.
Recognize That Aldolase Has Predictive Value
- Aldolase >9 U/L identifies SSc patients at high risk for developing subsequent myopathy within three years, even when CK is normal 5
- This allows for earlier intervention when muscle damage is still reversible 5
Distinguish Between Antibody Subtypes
- Testing only for anti-PM/Scl-100 will miss a significant proportion of SSc patients with anti-PM/Scl antibodies, as anti-PM/Scl-75 is actually more common in SSc (10.4% vs 7.1%) 1
- Anti-PM/Scl-75 associates with diffuse SSc, younger age, and joint contractures 1
- Anti-PM/Scl-100 associates with CK elevation and overlap syndromes 1
Functional Assessment Limitations
- Standard functional muscle tests validated for primary myositis (MMT-8, FI-2) do not perform well in SSc-myopathy due to confounding from skin, joint, and cardiovascular involvement 3
- Clinical assessment of proximal weakness remains important despite normal enzymes 2
Prognostic Implications
The presence of proximal weakness, regardless of CK elevation status, identifies SSc patients with significantly worse prognosis 2. Even patients with weakness and normal CK have doubled mortality risk, emphasizing that clinical assessment supersedes laboratory values in risk stratification 2.
The anti-PM/Scl antibody-positive phenotype is associated with younger age at disease onset, skeletal muscle involvement, calcinosis, inflammatory arthritis, and overlap disease, but notably less frequent interstitial lung disease and gastrointestinal symptoms compared to other SSc patients 10.